Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Acic Cold Sore 5% w/w Cream
Medicines register · Ireland

Acic Cold Sore 5% w/w Cream

Authorisation PA0711/017/006 · Rowex Ltd

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 21 Nov 2026
Licence holder
Rowex Ltd (all products →)
Active substance
Aciclovir
Dosage form
Cream
Route of administration
Cutaneous use
ATC codes
D06BB, D06BB03
First authorised
23/11/2012
Prescription status
Product not subject to medical prescription
Supply
Supply through non-pharmacy outlets and pharmacies
Legal basis
Informed consent application (Article 10c of Directive No 2001/83/EC)

Aciclovir: supply and approvals

18 authorised products on the HPRA list contain Aciclovir. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 20 Nov 2026)
Germany (BfArM)
3 supply notices, e.g. Aciclovir-ratiopharm 50 mg/g Creme (16 Feb 2026 to 29 Mar 2027)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 13 years (since 23 November 2012). The HPRA list marks it as marketed in Ireland.

Other medicines with Aciclovir in Ireland

17 other products on the HPRA list contain Aciclovir, from 13 licence holders; 9 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Aciclovir 200 mg/5ml Oral SuspensionSyri Pharma Limited t/a Thame LaboratoriesNational authorisation (PA)Marketed
Aciclovir 25mg/ml concentrate for solution for infusionPfizer Healthcare Ireland Unlimited CompanyNational authorisation (PA)Marketed
Aciclovir Agepha 30 mg/g eye ointmentAGEPHA Pharma s.r.o.National authorisation (PA)Marketed
Aciclovir Azevedos 250 mg Powder for solution for infusionLaboratórios Azevedos - Indústria Farmacêutica S.ANational authorisation (PA)Marketed
Viralief 50 mg/g CreamClonmel Healthcare LtdNational authorisation (PA)Marketed
Zovirax 200 mg Dispersible TabletsGlaxoSmithKline (Ireland) LimitedNational authorisation (PA)Marketed
Zovirax 200 mg/5 mL Oral SuspensionGlaxoSmithKline (Ireland) LimitedNational authorisation (PA)Marketed
Zovirax Cold Sore 5% w/w CreamHaleon Ireland LimitedNational authorisation (PA)Marketed
Zovirax IV for Infusion 250 mg, Powder for solution for infusionGlaxoSmithKline (Ireland) LimitedNational authorisation (PA)Marketed
Acic 5% CreamRowex LtdNational authorisation (PA)Not marketed
Aciclovir 250 mg powder for solution for infusionNoridem Enterprises LimitedNational authorisation (PA)Not marketed
Aciclovir 25mg/ml Concentrate for solution for infusionBaxter Holding B.V.National authorisation (PA)Not marketed

All 18 products with Aciclovir →

Other substances in ATC group D06BB

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 7 other active substances share the group D06BB with this product:

Imiquimod (2) · Green tea dry extract (1) · Penciclovir (1) · Podophyllotoxin (1) · Acyclovir (1) · ACICLOVIR PH. EUR. (1) · HYDROCORTISONE PH. EUR. (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Rowex Ltd holds 24 products on the HPRA list, with 17 different active substances; 19 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.